Evidence map›Paper›PMID 31010180›Full record

ReviewNanomaterials (Basel, Switzerland)2019

Lipid-Based Nanoparticles: Application and Recent Advances in Cancer Treatment.

Beatriz García-Pinel, Cristina Porras-Alcalá, Alicia Ortega-Rodríguez, Francisco Sarabia, Jose Prados, Consolación Melguizo, Juan M López-Romero

Open access · goldAbstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 167 papers.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 503 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Beatriz García-PinelInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), University of Granada, 18100 Granada, Spain. beatrizgarnel@correo.ugr.es.
Cristina Porras-AlcaláDepartment of Organic Chemistry, Faculty of Sciences. University of Málaga, 29071 Málaga, Spain. cristinaalcala@uma.es.
Alicia Ortega-RodríguezDepartment of Organic Chemistry, Faculty of Sciences. University of Málaga, 29071 Málaga, Spain. aliorterodri@uma.es.ORCID 0000-0001-7469-6723
Francisco SarabiaDepartment of Organic Chemistry, Faculty of Sciences. University of Málaga, 29071 Málaga, Spain. frsarabia@uma.es.ORCID 0000-0002-5149-3576
Jose PradosInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), University of Granada, 18100 Granada, Spain. jcprados@ugr.es.
Consolación MelguizoInstitute of Biopathology and Regenerative Medicine (IBIMER), Biomedical Research Center (CIBM), University of Granada, 18100 Granada, Spain. melguizo@ugr.es.
Juan M López-RomeroDepartment of Organic Chemistry, Faculty of Sciences. University of Málaga, 29071 Málaga, Spain. jmromero@uma.es.ORCID 0000-0003-2422-655X
Universidad de Málaga · ESUniversidad de Granada · ES

Funding

CICYT CTQ16-76311Consejería de Salud de la Junta de Andalucía PI-0102-2017Consejería de Salud de la Junta de Andalucía PI-0476-2016
6 · The paper itself

Abstract

Many therapeutically active molecules are non-soluble in aqueous systems, chemically and biologically fragile or present severe side effects. Lipid-based nanoparticle (LBNP) systems represent one of the most promising colloidal carriers for bioactive organic molecules. Their current application in oncology has revolutionized cancer treatment by improving the antitumor activity of several chemotherapeutic agents. LBNPs advantages include high temporal and thermal stability, high loading capacity, ease of preparation, low production costs, and large-scale industrial production since they can be prepared from natural sources. Moreover, the association of chemotherapeutic agents with lipid nanoparticles reduces active therapeutic dose and toxicity, decreases drug resistance and increases drug levels in tumor tissue by decreasing them in healthy tissue. LBNPs have been extensively assayed in in vitro cancer therapy but also in vivo, with promising results in some clinical trials. This review summarizes the types of LBNPs that have been developed in recent years and the main results when applied in cancer treatment, including essential assays in patients.

Indexed as

cancerclinical trialsdrug releasedrug resistancelipid-based nanoparticles

Identifiers

PMID31010180
PMCPMC6523119
OpenAlexW2936858823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.